TP53 and plasma cell myeloma: Further analysis of patients with myeloma who exhibit BCMA antigen loss suggested del16p appeared to be associated with concurrent del17p mutations, suggesting that resistance to BCMA-directed immunotherapies is more likely to develop in TP53-mutated myeloma [21].